A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...